Brentuximab vedotin is a monoclonal antibody-drug conjugate directed against the protein CD301. Brentuximab vedotin is indicated for treating patients with CD30+ Hodgkin lymphoma (HL) for which treatment with autologous stem cell transplant (ASCT) or 2 previous chemotherapy treatments have failed and when ASCT or chemotherapy are contraindicated.1
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2qNhsct
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.